- •Bempedoic acid (BA) reduces hsCRP with minimal effect on fibrinogen, IL-6, or Lp(a).
- •No correlation between lipid changes and hsCRP changes with BA.
- •Findings for BA are almost identical to that of statin therapy.
- •BA may be an option to treat residual inflammatory and residual cholesterol risk.
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Journal of Clinical Lipidology
- Safety and efficacy of bempedoic acid to reduce LDL cholesterol.N Engl J Med. 2019; 380: 1022-1032
- Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR Wisdom randomized clinical trial.JAMA. 2019; 322: 1780-1788
- Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study.Atherosclerosis. 2018; 277: 195-203
- Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance.J Am Heart Assoc. 2019; 8e011662
- Rationale and design of the CLEAR-outcomes trial: evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance.Am Heart J. 2021; 235: 104-112
- Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators.Circulation. 1999; 100: 230-235
- Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study.JAMA. 2001; 286: 64-70
- Residual inflammatory risk: addressing the obverse side of the atherosclerosis prevention coin.Eur Heart J. 2016; 37: 1720-1722
- IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial.Lancet. 2021; 397: 2060-2069
- Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.N Engl J Med. 2008; 359: 2195-2207
- Antiinflammatory therapy with canakinumab for atherosclerotic disease.N Engl J Med. 2017; 377: 1119-1131
- Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin).Circulation. 2014; 129: 635-642
- Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial.Circulation. 2003; 107: 2409-2415
- Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance.J Clin Lipidol. 2016; 10: 556-567
- C-reactive protein, interleukin-6, and risk of developing type 2 diabetes mellitus.JAMA. 2001; 286: 327-334
- Efficacy and szfety of bem[pedloic acid for the treatment of hypercholesterolemia: a systematic review and meta-analysis.PLoS Med. 2020; 17e11003121https://doi.org/10.1371/journmal.pmed.1003121
- Effects of randomized treatment with icosapent ethyl and a mineral oil comparator on interleukin-1β, interleukin-6, C-reactive protein, oxidized low-density lipoprotein cholesterol, homocysteine, lipoprotein(a), and lipoprotein-associated phospholipase A2: a REDUCE-IT biomarker substudy.Circulation. 2022; 146: 372-379
- Statin therapy increases lipoprotein(a) levels.Eur Heart J. 2020; 41: 2275-2284
Publication stageIn Press Journal Pre-Proof
Conflict of interest: Ridker: Dr. Ridker has received institutional research grant support from Novartis, Kowa, Amarin, Pfizer, Esperion, and the NHLBI; has served as a consultant to Novartis, Flame, Agepha, AstraZeneca, Janssen, Civi Biopharm, Glaxo Smith Kline, SOCAR, Novo Nordisk, Uptton, Omeicos, Health Outlook, Montai Health, New Amsterdam, Boehringer-Ingelheim, Angiowave, RTI; Zomagen, Cytokinetics, Horizon Therapeutics, and Cardio Therapeutics; and receives compensation for service on the Peter Munk Advisory Board (University of Toronto), the Leducq Foundation, Paris FR, and the Baim Institute (Boston, MA). Lei: Dr. Lei is an employee of Esperion Therapeutics. Ray: Dr. Ray has received institutional research grant(s)/support from Amgen, MSD, Pfizer, Regeneron, and Sanofi, and served as a consultant for or received honoraria from Abbott, Amgen, AstraZeneca, Boehringer Ingelheim, Cargene, CRISPR, Eli Lilly, Esperion Therapeutics, Kowa, Medicines Company, MSD, New Amsterdam, Novo Nordisk, Novartis, Pfizer, Regeneron, Resverlogix, Sanofi, Scribe Therapeutics, Vaxxinity, Viatris and Zuellig Pharma. Ballantyne: Dr. Ballantyne has received research grants/support from Abbott Diagnostics, Akcea, Amarin, Amgen, Esperion Therapeutics, Ionis, Novartis, Regeneron, Roche Diagnostic, Sanofi-Synthelabo, National Institutes of Health, American Diabetes Association and the American Heart Association (all paid to the institution, not to the individual); has also served as a consultant for Abbott Diagnostics, Amarin, Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Esperion, Intercept, Ionis, Matinas BioPharma, Merck, Novartis, Novo Nordisk, Regeneron, Roche Diagnostic, and Sanofi-Synthelabo. Bradwin: None. Rifai: None.
Author contributions: Concept and design: Ridker, Rifai; Acquisition, analysis, or interpretation of data: Ridker, Lei, Ray, Ballantyne, Bradwin, Rifai; Drafting of the manuscript: Ridker; Critical revision of the manuscript for important intellectual content: Ridker, Lei, Ray, Ballantyne, Bradwin, Rifai; Statistical analysis: Lei; Administrative, technical, or material support: Bradwin, Rifai; Supervision: None; Author access to data: Dr Ridker had access to all the study data and takes responsibility for the integrity of the data and the accuracy of the data analysis.